← Human Trials & Peer-Reviewed Studies
Administration of recombinant human growth hormone normalizes GH-IGF1 axis and improves malnutrition-related disorders in patients with anorexia nervosa.
Plain-language guide to PMID 17339748 (2007): controlled clinical trial of IGF-1 LR3 and Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 17339748
- Journal
- Endocrine journal
- Year
- 2007
- Study type
- Controlled Clinical Trial
- Authors
- Hashizume K et al. (11 authors)
- DOI
- 10.1507/endocrj.k05-178
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 and Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.
High serum level of GH in the presence of low plasma level of insulin-like growth factor-I (IGF-I) is one of the endocrinological features of anorexia nervosa (AN).
During each treatment, levels of serum GH, plasma IGF-I, serum thyroid hormones, serum cholesterol, fasting plasma glucose and cardiac function were monitored.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
How the Study Was Run
In design terms this was a placebo-controlled study.
The comparison arm used a placebo, so changes seen with IGF-1 LR3 could be set against what happens without it.
What Was Measured
High serum level of GH in the presence of low plasma level of insulin-like growth factor-I (IGF-I) is one of the endocrinological features of anorexia nervosa (AN).
During each treatment, levels of serum GH, plasma IGF-I, serum thyroid hormones, serum cholesterol, fasting plasma glucose and cardiac function were monitored.
The subject headings attached to it are Anorexia Nervosa, Attitude, Blood Glucose, Body Mass Index, Body Temperature, Cardiac Output and Cholesterol.
What This Means in Plain Language
The paper is a placebo-controlled study of IGF-1 LR3 and Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The publication is from 2007 (Endocrine journal), a journal based in Japan.
More context: the IGF-1 LR3 compound page and the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compounds
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
- IGF-1 LR3 in the library
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.